everyone. Steve and you, afternoon good Thank
quarter We pleased guidance are both second our that significantly results share revenue EPS. and to for very exceeded
business. performance diverse of once highlights strength Our second quarter our the again
base our our this impacted than quarter, offset stronger in uncertain key balance we also negatively environment. free capital important testing variant strategic to shortly. I the which of funding $XXX will cash operating significant second deployment our priorities. million detail more and generated continue repurchase, on flow to touch cash flow, In both understand our we very sheet Omicron executed this headwind. the COVID the Further, than quarter, share generate It’s businesses ever, upside in healthy providing While more of is flexibility early macro that in
Before for on that, our we color will we divisional consolidated do quarter. and provide second results the
lower patient than As in total than which came million second quarter, first our $X.X in a from very revenue guidance. our the calendar the before more revenue reminder, was activity year midpoint and of typically fiscal end. compared quarter, billion over is seasonally In our of benefits to strong higher increased quarter $XXX previous
In addition, $X.XX. to exceeded second in far $X.XX guidance $X.XX quarter the of our EPS range of
results. of Diagnostics, divisional our million $XXX.X year. to prior X.X% Turning to declined revenue compared global the In
COVID, X%. excluding increased worldwide organic However, revenue diagnostics
the Omicron COVID-XX discussed, impacted QX the in were division’s As by results negatively early variant.
spikes as surge. to visits correlated when diagnostics inversely tend cases postpone in business is COVID to women base the pandemic office Our
great cases of COVID us However, diagnostics underlying trends as were franchise. March by we declined. This base in health gives encouraged improving our confidence throughout the
diagnostics Moving in driven organically the line. virology was in and the these by revenue exclude our specifically our we molecular business, menu This will our second uptake within vaginitis Making newer product about grew of impact quarter. growth molecular base assays as such COVID. X% strong again to adjustments, panel
assay our of COVID we shipped million COVID as exceeding held about total million revenue. relates of We million. assay globally. guidance represented tests The COVID steady it United $XXX As XX% $XXX to generated States ASPs test customers to results, about around of $XX XX.X our far revenue, per
global our were as Diagnostics, these and essentially also However, cytology prior influence markets year women’s impacted testing well. segments In visits. flat international in Health, compared wellness on revenue needles. the million strong perinatal business, few as out were demand by to supply our discussed. COVID-XX’s Breast X% approximately our expected, was of businesses a driven $XXX.X of interventional quarter, have pressure by was shortages during the chip specific surfaced we as primarily million biopsy that incremental disposable to dollars In down chain the Rounding
in As business a down our slightly result, than interventional was less the X% period.
XXXX. commented, While challenges best-in-class million chain improvement as demand supply In of remain to $XXX.X grew products in Steve see And persist, our second X.X%. Surgical, strong. we revenue Breast for expect Health quarter
pullback the COVID of foreshadowed Furthermore, call, management contributions in first cool we caused sale several of elective Omicron quarter. nice later fluid in trend the resilience in a variant a Bolder’s saw this As such half cases from products Fluent improved devices. first But system procedures the from declined. as the our as quarter newer our period solid during the and we
prior to Lastly, our skeletal million business, $XX.X decreased year revenue the X% of compared period.
let’s non-GAAP quarter. P&L margin volumes Total of $XXX.X of XX% Now rest COVID-XX Gross increased our well of expenses second for driven million the second the the on higher-than-expected XX% operating forecast, to of move was period. testing by the ahead in the quarter. in
took the opportunity the have to we the our reinvest pandemic, done throughout As businesses. profitability, COVID-XX from we in base given benefit
to initiatives awareness We also women’s help key drive allocated marketing health. for spend to
included as these expenses quarter. and our combined partnership. total more slightly with contribute initiatives our Bowl associated to WTA the quarter operating million expenses operating as example, For expenses commercials Super than $XX of well in Olympic The second
operating addition, less slightly prior within period. recent quarter, the million acquisitions year In than expenses, than million the added higher about $XX $XX in
our XX.X% at earnings strong guidance. income than expectations came lower $XXX.X COVID-XX above our net our margin very nearly marginally prior Finally, these pieces QX together, at United at revenue States. was Non-GAAP was was Putting operating margin forecast XX.X%. million higher the XX.X%, the QX above finished outside of non-GAAP midpoint our in rate for well in $X.XX, the per and tax net XX% given share and
P&L. to the for refunds, was inclusive normalizing flexibility. second When approximately previously operations sale generation totaling the continue held $XXX and Aesthetics the cash financial quarter, tax cash for million business exceptional. of These billion from Cash still related to $X.XX robust refunds tremendous flow the on flows in to these in quarter Medical Moving provide XXXX. was of our strategic
in earlier, shares quarter. referred repurchased as our X.X for million example, the to we stock million For of $XXX
opportunities share ongoing continue a to the to on to we leverage performance, lever M&A we view We quarter, each cash of $X.X of Further, drive one ratio sheet Based in our our operational X.Xx. at our continue of as our for value second repurchase had divisions. on and pursue the program our billion balance shareholders. was our strong diligently end
opportunities. we as discipline quarter to with Our ended be an is capital in structure fortified. elevated we cash balance, thorough And while the exercise continue we evaluate
the we in comfort Given high-quality the our have balance with ability macro elevated as be cash patient opportunities. to environment, identify we
we year Now let’s move million on XXXX. $XXX third to our updated guidance for results the the our third delivering In quarter fiscal quarter, in and of revenue million. total of to track range to financial with continue $XXX full expect record the strong
the full XXXX, midpoint. in the exceeding year full to revenue year fiscal range significantly at For $X.X prior $XXX of the expect guidance our we total $X.X million by billion, billion
uncertain macro We are confidence raising face in of guidance the an business. our our in backdrop, once again highlighting
quarter. constant currency $XX quarter to the headwinds $XX is revenue our drive based to of X,XXX molecular pandemic. on of than growth start our instruments Diagnostics, expect the guidance approximately strength XXXX with the third million This million aid of unfavorability year. the Panther in modeling, XX% last full FX of assuming globally, and than installed foreign exchange continue over Given to we and the of larger dollar continued higher for the In base U.S. from are we to over
our panel, as also uptake seeing are vaginitis assays tremendous encouraging international expansion Amgen of as newer our like and the well opportunities. We virals
expected quarter COVID the approximately are full the to in discontinued inclusive of least product billion small well $XX and sales, $X.XX $XXX to the related full In for year. amount million of perform and expect XXXX in the our third division’s streams. a of million of In year. $XXX Breast items, the COVID at third to terms highlight Health, the continue revenue of we investments sales organic for inorganic be be quarter assay diversity COVID revenue million and and approximately
great quarter. last mid-teens For had example, another result, Brevera the in growing
service addition, XX% than revenue represented in total sales recurring In QX. of more
chip exist into Breast in in exists, uncertainties an of XXXX the quarter, In and million half terms announced incremental $XX significant possibility the incorporated given our guidance. the last of Health still have back this market the headwind shortage chip we of
While issue forecasting we are this supply, we early supply chip To improvement of purely and in not headwind demand, are of underlying reemphasize signs seeing a conservatively. is one strong. remains which
Surgical, drive the over Fluent as in organic we we products and continue growth about from of trends meaningful Boulder both Finally, expect feel trajectory related as the Acessa great next improve. MyoSure and to business near-term and several our such years. contribution COVID
from guidance our as backs quarter full revenue as divested annualizes until our deal acquisitions reminder, a business. well organic a revenue blood first of from out after As the screening
Diagenode and the only. in Therefore, part revenue the Mobidiag of Boulder terms and revenue adjustments for for organic organic our Biotheranostics QX will ‘XX. In deal, includes QX become of Boulder QX and
the down Moving P&L.
the forecast to operating gross than last quarter. half our XXs For the we revenue mid- non-GAAP margin our second our Breast in impact full percentage margin estimates and to be supply percentage Both the chain high are guidance be to XXs. high margin incorporates from Further, year, guidance our non-GAAP higher shortfall. in Health the our
receive margin accretive order in averages, a position have gross to operating be As quickly the we maintained a in reminder, chips. to move to spend and once consolidated we Gantry is
full In be and have electronics, as guidance headwinds, the levels. operating year, costs to expect gross inflationary we above these addition, relates we incorporated supply again it to margins and Despite logistics. plastics both our chain pre-pandemic into for
compared expect expenses, to spending half XXXX be up to of to XXXX, the half. lower be In second in the but terms of operating compared first we
take higher a million little be operating invest less income, year. other with quarters to for future COVID expect in highlight, the net $XX than the to we we the quarter continued Below a for testing expenses remainder of to opportunity have will we growth. As revenue,
Our full net million $X.XX the above to All to diluted for to on the XX% our this guidance rate outstanding guidance third $X.XX $XXX is based XX% year. quarter of of $X.XX shares add year, EPS midpoint. and around effective and $X.XX at tax full for in of the expected prior the
upsides you encourage update challenges model geopolitical to forecast, middle that macro me remain our uncertainty would the related remind and We let conflicts supply at the which therefore your of incorporates pandemic both to chain you potential As downsides. you due high. ranges, and
by saying quarter up wrap me expectations strong Let Hologic exceeded guidance. and that second far very results that posted
also for guidance financial We raising our year. the are
supply we flow the growth drivers as well Even are positioned. franchises questions. from each ask we increasing anticipated of our highlighting benefits balance headwinds, cash the chain we are generation, open testing. that, sheet operator for call a best-in-class to and added With multiple have With and strong to the COVID we